TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
Donald Freudenstein, Cassandra Litchfield, Franco Caramia, Gavin Wright, Benjamin J Solomon, David Ball, Simon P Keam, Paul Neeson, Ygal Haupt, Sue Haupt
Cancers | MDPI | Published : 2020
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as p..View full abstract
This research was funded by the Peter MacCallum Foundation and the Sister Institution Network Fund (SINF): MD Anderson-Peter Mac.